The authors identified BPC-157 as having significant potential and described it as a feasible therapy candidate for conservative treatment of hypovascular and hypocellular soft tissues such as tendon and ligaments, following further development
Pillai, United States Department of Health and Human Services, United States Reviewed by Xiaojia He, Emory University, United States Daniel Gonzalez Carter, Institute for Bioengineering of Catalonia (IBEC), Spain Updates Copyright 2022 Zhang, Xiong and Liu
Knowing how to switch between mcg and mL helps ensure patients get the right dose, leading to better results
(An HHS spokesperson said the FDA would not comment on the agencys enforcement policies for BPC-157 and other unapproved peptides.) For his part, Lee founded the nonprofit Save Peptides, which has launched a petition asking lawmakers to intervene